Biotech M&A Tracker 2026

A transatlantic rescue in both directions. Skye had a failed obesity thesis and a listing; Redx had a Fast Track fibrosis asset and a UK small-cap market that would not fund it. The ownership split tells the story — legacy Skye holders keep 5.38% and the new money takes 48.45%, so this is a recapitalisation dressed as a merger, with the CVR on nimacimab the only claim Skye shareholders retain on the old business. For UK biotech it is another company leaving AIM for Nasdaq via a shell rather than IPOing at home. The timeline is the weakness: Phase 2 topline in H2 2028 against runway through 2029 leaves almost no margin.

The end of one of the original genomic medicine platform companies, and a reminder of what platform value is actually worth in a forced sale — Lilly picked up the capsid, zinc finger and MINT technology plus a prion programme for US$50M, less than a single Series A. The clinical asset carried the price: PTC paid US$111M plus US$100M in milestones for a BLA-stage Fabry therapy with 4.5-year durability data in early patients and roughly 11,000 US patients addressable, competing with an entrenched enzyme replacement standard. Astellas set the floor as stalking horse and lost. For PTC it is a fast, cheap route into a commercial rare-disease category; the risk is that Fabry gene therapy has to displace a therapy patients tolerate.

Jazz is paying US$820M in cash for a Phase 1b/2a asset in roughly 2,500 US patients — an aggressive price per patient that only works because the RDEP designation offers a credible route to approval on a single small registrational trial. It is a deliberate rebuild of the epilepsy franchise around genetically defined populations rather than another Epidiolex-style broad label, and it lands as Jazz needs pipeline ahead of Xywav erosion. The spinout structure is the interesting mechanic: Jazz buys precisely the one programme it wants, leaves the TRPV4 work with the team that built it, and keeps a minority option on the upside. Risk is concentrated — a single early-stage asset with no controlled efficacy data, and a target population small enough that trial execution is the whole thesis.

Tarsus extends beyond Xdemvy into inherited retinal disease and pays for it without touching the balance sheet — the US$125M PIPE comes from Alkeus’s own crossover investors, which is as close to a self-funding structure as an eye-care bolt-on gets. Stargardt has no approved therapy and roughly 36,000 US patients, but Belite Bio’s tinlarebant has already won its Phase 3 and is in front of the FDA, so Tarsus is buying second position in a race it does not lead. The pivotal readout is 2029, making this a long-dated option rather than a near-term revenue event, and the asset carries a prior Phase 3 miss in geographic atrophy.

At ~3x revenue for the plumbing behind implantable devices, KKR is re-rating device manufacturing capacity while strategics keep capital pointed at drug pipelines. It is the third sizeable sponsor take-private in healthcare in quick succession after Blackstone/TPG-Hologic (up to ~US$18.3B) and American Industrial Partners-Avanos (US$1.27B), and prints a clean scale comp for medtech CDMO assets. Open risk is regulatory review.

Hinge (NYSE: HNGE) extends from musculoskeletal into digestive care, the second-largest employer-benefit spend category after MSK, using a small all-cash bolt-on rather than building. It lands alongside Q2 revenue of US$213M (+53%) and full-year guidance raised to US$856–860M, so the deal reads as a category-expansion move made from strength — and it prints a benchmark for virtual specialty-care assets at roughly the scale employers actually buy.

Curium is buying the toll booth rather than another radioligand. Novartis widened Pluvicto into PSMA-positive mHSPC on 31 July, roughly doubling the eligible pool, and Pylarify is the scan that decides who qualifies — so Curium takes economics one notch upstream of therapy. LNTH added only 2.45% on the news because Bloomberg leaked the process in May and did the repricing then, and the tape is marking the CVR stub close to zero against an H1 2027 close. Two risks worth pricing: antitrust review of combined isotope supply, and a target that had suspended 2026 guidance and pulled its 6 August call.

Two mid-cap CNS names combine rather than sell, building a diversified US$2.2B-revenue commercial platform with real cost overlap — US$125M of synergies against US$888M of pro forma EBITDA. The US$1B pre-closing special dividend, part debt-funded, is the mechanism that squares the exchange ratio, and it leaves the combined balance sheet more levered than either standalone. For the sector, it is a reminder that scale in specialty CNS is still being built by consolidation rather than by pipeline.

The same week as Curium/Lantheus, and the same thesis: capital is chasing isotope supply and radiopharmaceutical manufacturing capacity rather than the radioligands themselves. Nordic Capital gets a scaled isotope platform at a moment when therapeutic isotope supply is a binding constraint on the whole class; BWXT keeps optionality through a retained minority stake and a continuing supply role while redeploying proceeds to its nuclear national security and commercial power core.

argenx converts a four-month-old strategic stake into a full takeover, adding a second mechanism (CD122) alongside its FcRn franchise and reopening the biotech M&A window with its first takeout in a while. At ~$2.2B for a Phase 1b asset, argenx is paying up for early validation rather than de-risked data, betting the pipeline-in-a-product thesis holds across vitiligo, celiac and alopecia — and printing a clean $2.2B comp for the anti-CD122 / IL-15 autoimmune class.

Dassault folds a scaled, AI-enabled life-sciences compliance layer into its 3DEXPERIENCE stack, aiming to build the industry’s first unified intelligence platform connecting molecule, patient and real-world outcomes. A software/infrastructure deal that underscores how central regulated safety and regulatory-affairs workflows have become, and how buyers are paying up for AI-native platforms embedded in biopharma operations.

Repligen buys a mission-critical cell-therapy input rather than build it, lifting new modalities to ~25% of revenue and betting on 20%+ annual growth in commercial cell therapies. A tools/infrastructure deal that underscores how central reliable biopreservation and bioprocessing supply have become as cell therapy scales, and how costly it is to switch suppliers late in development.

Korea’s largest-ever biopharma deal and a direct bet on the scarcest input in the GLP-1 boom — peptide API capacity, which cannot be built greenfield on a short timeline. Samsung Biologics chooses to buy scaled peptide manufacturing outright rather than build it, underscoring how tight obesity-drug supply chains have become; Bachem is the read-across on any re-rating of listed peptide capacity.

Brings MRD — the fastest-growing slice of liquid biopsy — in-house for Tempus and sets a valuation marker for tissue-informed residual-disease testing. The thin premium and all-stock structure drew a mixed market reaction (Tempus shares slid), signaling investors want MRD accretion proven rather than promised, but the deal consolidates a high-growth diagnostics niche under an AI-driven data platform.

A full strategic remake: Jasper pivots into immunology via Kira’s biologics and a fresh ~US$132M raise, while carving out non-core programs to Mirador. It illustrates the recapitalization-and-refocus route small public biotechs are using in 2026 to refresh both pipeline and balance sheet.

Lilly’s largest move into psychiatry and its formal entry into the psychedelics space, coming after J&J’s Spravato validated a certified-clinic esketamine franchise now running above US$1B annually. BPL-003’s roughly two-hour in-clinic session is materially shorter than psilocybin’s six-to-eight-hour window, a potential commercial differentiator versus Compass and Definium. The deal signals that Big Pharma increasingly views psychedelics as a real, scalable category rather than a fringe bet, and puts pressure on other clinical-stage psychedelic names as potential targets.

Vertex is making its largest acquisition to date and using M&A to establish endocrinology as a fifth therapeutic area beyond cystic fibrosis, hematology, pain, and renal disease. Crinetics adds a commercial rare-endocrine launch plus a late-stage CAH asset, giving Vertex a potentially multi-blockbuster specialty franchise and showing that buyers remain willing to pay very large premiums for de-risked rare-disease platforms with near-term revenue and pipeline depth.

Novartis is buying into a differentiated ADC payload platform rather than just another target-specific ADC, adding potential first-in-class NMT inhibitor payload biology with applicability across multiple solid tumor settings. The deal reinforces sustained strategic appetite for next-generation oncology modality platforms, especially where the payload could overcome limitations of established TOPO-1-based ADC approaches.

Ipsen is adding its second biotech acquisition in the same week, this time strengthening rare disease with a clinical-stage transplant-infection asset where there are no targeted approved treatments. The deal is smaller than Kartos but strategically consistent: Ipsen is using external innovation to build depth across rare disease, oncology and neuroscience, while Memo gives it a first-in-class antibody with fast-track designation and a near-term pivotal path.

A public biotech buying another public biotech to add near-term commercial cash flow rather than a classic Big Pharma pipeline takeout. Zymeworks is using Theravance to diversify beyond oncology and bring in Yupelri economics that can help fund its development pipeline. The negative/discounted premium and CVR structure make it a useful marker of distressed or strategic-alternative-driven M&A rather than a hotly contested premium takeout.

Ipsen is adding a late-stage hemato-oncology asset that could become a new option for myelofibrosis patients with inadequate response to ruxolitinib, with Phase 3 POIESIS top-line data expected in 2027 and a potential launch as early as 2028. The deal reinforces strategic appetite for clinically advanced hematology assets where the biology is targeted, the unmet need is clear, and the buyer can build a broader oncology franchise around a near-term registrational program.

A high-signal biopharma-enabling infrastructure takeout rather than a therapeutic pipeline acquisition. Merck KGaA is using a large-scale public M&A deal to strengthen its Life Science division, deepen exposure to biological research, cell and gene therapy workflows, multi-omics, and precision diagnostics, and consolidate tools that sit upstream of drug discovery and biomanufacturing. The deal is large enough to reshape the 2026 M&A leaderboard and reinforces that strategic M&A is extending beyond drugs into the enabling rails of biotech R&D and manufacturing.

AbbVie is making one of the largest biotech acquisitions of 2026 to deepen its next-generation immunology pipeline and defend long-term leadership beyond Skyrizi, Rinvoq, and Humira. Apogee brings a late-stage long-acting IL-13 program with potential dosing differentiation versus existing type 2 inflammation biologics, plus a broader antibody pipeline across dermatology and respiratory indications.

Biogen is continuing its pivot beyond legacy neurology by adding another immunology platform shortly after the Apellis acquisition. RayThera is early-stage, but the deal is strategically relevant because it adds multiple anti-inflammatory assets and reinforces Biogen's effort to build a broader immunology pipeline through private-company M&A and business development. Closed 6 August 2026 with the lead program already dosing in Phase 1, so the first milestone tranche is live rather than hypothetical.

Lilly is adding another non-opioid pain platform after its earlier SiteOne acquisition, using small private-company M&A to build optionality in a large neuroscience category where it has already had setbacks. The deal is strategically relevant because 4E brings a first-in-human MNK inhibitor approach designed to interrupt peripheral pain signalling without central nervous system effects such as addiction or cognitive impairment.

GSK is making its largest deal in more than a decade to rebuild scale in oncology, adding two near-launch lung cancer assets with potential multi-blockbuster positioning. The transaction is strategically notable because it moves GSK beyond smaller bolt-ons and gives new CEO Luke Miels a high-conviction precision-oncology platform ahead of the dolutegravir loss-of-exclusivity period.

Incyte is using M&A to add a late-stage rare hematology asset as it diversifies beyond Jakafi. The deal is notable because Vega brings a Phase 3 program in von Willebrand disease with meaningful commercial optionality, and Incyte is committing substantial upfront capital to expand its hematology footprint ahead of looming portfolio transition pressure.

J&J is buying into the degrader-antibody conjugate wave, adding Firefly Bio's Firelink platform as a differentiated oncology modality. The deal reinforces continued strategic appetite for next-generation targeted oncology platforms, particularly where antibody targeting can be paired with protein degradation to create a broader pipeline rather than a single asset.

Servier is buying a late-stage rare-neurology asset and associated capabilities rather than a whole public company, giving it a credible muscular-dystrophy franchise while Edgewise refocuses on cardiovascular disease. The deal is strategically notable because Servier is paying meaningful upfront capital ahead of pivotal BMD data expected this year, underlining appetite for rare neuromuscular assets with differentiated, non-dystrophin biology.

Part of Lilly's three-deal push back into infectious disease prevention. Curevo gives Lilly a clinically advanced shingles vaccine challenger with a tolerability-led positioning angle — a reminder that vaccine M&A can be strategic again when the asset targets large adult populations and could improve adherence versus entrenched incumbents.

The highest-value of Lilly's three vaccine acquisitions and strategically notable because EBV biology sits at the intersection of infectious disease, neurology, and oncology risk. For investors, the read-through is that Big Pharma may again underwrite prevention platforms where the pathogen has links to long-term, high-cost disease rather than only acute infection.

Adds bacterial-vaccine capability to Lilly's revived infectious-disease franchise. The strategic signal is that pharma appetite is not limited to viral vaccines: prevention of high-burden bacterial complications such as surgical-site infections can still attract M&A if the platform creates a pipeline of pathogen-specific shots.

A sponsor-led specialty-pharma take-private rather than a pipeline biotech takeout, but too large to ignore. The deal shows that private capital remains willing to underwrite scaled commercial biopharma assets with rare-disease exposure, even where the strategic logic is portfolio durability, operating control, and delisting rather than single-asset R&D upside.

A smaller and higher-risk public-acquirer / private-target transaction, but relevant as a recapitalization-style oncology platform deal. Liminatus is using stock to pivot toward CAR-T optionality despite limited cash, showing how distressed or microcap biotechs may use M&A to rebuild pipeline narratives when conventional financing remains constrained.

A platform tuck-in that extends Lilly's genetic-medicine toolkit rather than adding a near-term clinical asset. The read-through is that delivery remains a strategic bottleneck: large pharmas are willing to buy enabling technologies that could improve potency, tolerability, redosing, or tissue localization across broader genetic-medicine portfolios.

Angelini is using M&A to enter the U.S. market and scale its brain-health / rare-disease presence around a commercial neuromuscular platform. The read-through is that commercial rare-disease assets with concentrated specialist infrastructure remain strategic — particularly for ex-U.S. buyers seeking a U.S. beachhead rather than building one organically.

Not a therapeutic pipeline takeout — a high-signal biopharma-enabling infrastructure deal. Roche is folding PathAI into its Diagnostics division to deepen digital pathology and AI-enabled companion diagnostics, reinforcing that strategic M&A is increasingly extending from drugs into the data and diagnostic rails that shape precision-medicine adoption.

Strategically notable because Pathos is positioning it as an AI-sourced clinical oncology acquisition. The read-through is that AI-native developers are starting to use proprietary asset-screening platforms not just to design programs internally, but to identify and buy clinical-stage assets with differentiated early data.

Bayer is adding a clinical-stage ophthalmology asset and mechanism that could broaden its eye-care pipeline beyond existing retinal franchises. Ophthalmology remains a live M&A lane when the target offers a differentiated biology angle and a plausible path into large, high-burden diseases such as glaucoma and diabetic retinopathy.

UCB is doubling down on immunology with a platform-style acquisition built around T-cell engagers for autoimmune disease. The deal reinforces the broader sector push toward immune reset approaches, where oncology-derived modalities are being repurposed for chronic autoimmune indications with potentially deeper and more durable efficacy.

A public-to-private commercial-stage cardiovascular takeout rather than a classic discovery-platform deal. The read-through is that financial sponsors are prepared to underwrite commercial execution where public markets have struggled to price specialty-pharma assets — especially with an approved product base and clearer operating levers outside the public-company spotlight.

Chiesi is buying a near-commercial rare-disease asset that could change the HAE treatment paradigm by moving on-demand therapy toward an oral option. Strategics will pay meaningful premiums for late-stage / launch-ready rare-disease assets where convenience can drive differentiation and the buyer can plug the product into an existing rare-disease infrastructure.

Teva is adding an NDA-ready neuroscience asset that fits its pivot toward branded growth and specialty neurology. Buyers are willing to pay for late-stage CNS assets when the regulatory path is close and the product can slot into an existing commercial footprint — even in indications that historically have seen limited therapeutic innovation.

Shows consolidation in royalty aggregation. The read-through is that royalty portfolios remain attractive strategic assets when acquirers can combine diversified cash-flow streams, lower public-company costs, and create scale in non-dilutive biopharma financing infrastructure.

Lilly is again using private-company M&A to deepen oncology / hematology exposure, this time around a potentially differentiated JAK2 profile in MPNs. Strategic appetite remains strong for targeted hematology assets when the mechanism is validated but the product profile could still improve on tolerability, selectivity, or depth of response.

The largest disclosed 2026 biopharma M&A deal on the tracker — more about commercial scale than single-asset R&D risk. Sun Pharma is using M&A to add a global branded portfolio, women's-health infrastructure, and biosimilar exposure, reinforcing that strategics will pay up for durable commercial platforms when growth, geographic reach, and portfolio breadth are immediately accretive.

A scale-and-integration deal: Amneal is buying Kashiv to turn an existing biosimilar partnership into a fully integrated global platform. Biosimilars are becoming an M&A lane in their own right as companies position for the next biologics LOE wave and try to control development, manufacturing, and commercial economics under one roof.

Lilly is making another major platform bet to expand beyond obesity and deepen its oncology footprint, this time around in vivo CAR-T. Strategically, the deal signals real appetite for approaches that could simplify cell-therapy logistics and potentially widen access if in vivo delivery proves clinically durable.

UCB is using M&A to push beyond conventional epilepsy pharmacology and establish a position in advanced regenerative therapies. Large-cap CNS buyers are increasingly willing to underwrite platform and modality risk when it could produce disease-modifying benefit in entrenched, high-burden neurological conditions.

Another sign that Lilly is actively building oncology depth through targeted tuck-ins rather than waiting only for large public takeouts. The strategic logic is platform-driven: dual-payload ADCs could offer a path to more durable responses and better resistance management in solid tumors.

Gilead is expanding beyond cell therapy and immunology into a deeper ADC capability set — buying not just a clinical ovarian-cancer asset but differentiated linker-payload and conjugation technology. Buyers are still willing to pay heavily for clinically anchored oncology platforms when they can strengthen a broader franchise rather than add a single isolated asset.

Neurocrine is buying a newly launched, already de-risked rare-disease product and using M&A to extend beyond neuroscience into endocrinology / metabolic disease. Buyers are still willing to pay meaningful control premiums for approved assets with visible commercial traction, especially where the target opens a new franchise lane rather than just adding pipeline optionality.

Biogen is buying immediate commercial revenue plus a broader complement platform at a time when it needs new growth vectors beyond legacy MS. The deal adds approved rare-disease and retinal assets today while giving Biogen a more credible foothold in nephrology ahead of its broader immunology build-out.

Lilly is paying up to secure a clinically de-risking orexin agonist platform and enter sleep medicine with a potential best-in-class wakefulness asset. Large-cap buyers are willing to underwrite differentiated neuroscience mechanisms when there is clear biology, sizable commercial white space, and room to build a broader franchise around the lead program.

Otsuka is making a meaningful bet on the next wave of neuropsychiatry by buying a company built around rapid-acting, psychedelic-adjacent medicines. Large buyers are willing to underwrite differentiated CNS mechanisms where the clinical need is large and the commercial white space remains open.

Novartis is doubling down on allergy with a differentiated anti-IgE asset that could help defend and extend the franchise around proven IgE biology as Xolair matures. The key strategic question is whether Exl-111 can offer a meaningfully better efficacy / convenience profile and become the next-generation backbone in food allergy and adjacent IgE-driven settings.

Merck is paying up for a late-enough oncology asset with a plausible commercial lane in CML as it works to deepen its post-Keytruda pipeline. Strategic buyers still want differentiated hematology / onco assets, especially where there is a credible best-in-class argument.

Gilead is leaning harder into autoimmune disease with an "immune reset" style asset that could broaden its inflammation franchise beyond its historical core — and adds another meaningful strategic use of capital soon after the Arcellx deal.

Servier is buying a commercial rare-oncology platform rather than just a development story, pairing pediatric low-grade glioma with its existing neuro-oncology footprint and paying a clear control premium for an already de-risked asset base.

Not a classic venture-biotech platform buyout: Esperion is using M&A to add a commercial cardiovascular product and broaden its franchise beyond cholesterol-lowering.

GSK is paying a meaningful sum for a private clinical-stage cardiopulmonary asset that could strengthen its respiratory and inflammation franchise — placing it into an increasingly important pulmonary hypertension strategic lane.

Gilead buys out its partner to take full control and economics of anito-cel ahead of a potential launch — accelerating development and commercialisation while eliminating the existing profit-share, milestones, and royalties.

More merger-like than a classic cash buyout — but still a control transaction that recapitalizes a struggling public biotech around a new oncology asset base and fresh private financing.

Lilly's entry into in vivo CAR-T — aiming to turn cell therapy from a bespoke, ex vivo manufacturing model into something more scalable and potentially usable across broader autoimmune indications.

Broadens Halozyme's delivery stack beyond ENHANZE, adding a differentiated formulation capability that could expand the set of biologics feasible for at-home SC dosing and support additional partnering / royalty pathways.

Bolt-on to deepen GSK's immunology pipeline with a clinically validated target and a potential longer-dosing-interval anti-IgE profile.

Adds a clinical-stage oral inflammation pipeline — notably NLRP3 and IBD mechanisms — to extend Lilly's immunology footprint beyond incretins.

Expands Amgen oncology pipeline with a first-in-class targeted protein degradation approach in AML — a high unmet-need setting.